Molecular and phenotypic characterization of invasive group B streptococcus strains from infants in Norway 2006–2007

Bergseng, Håkon; Afset, Jan Egil; Radtke, Andreas; Loeseth, K; Lyng, Randi Valsø; Rygg, Marite; Bergh, Kåre

doi:10.1111/j.1469-0691.2009.02789.x

Cited by 18 publications

(15 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Belgium, as determined by the National Reference Centre for GBS, macrolide resistance increased from 10.4% in the early 2000s to 33% among invasive strains isolated from 2008 to 2011 [59]. These figures are consistent with similar reports from Europe [61][62][63][64][65], North America [60,[66][67][68][69][70], and Asia [71,72], except some surveillance studies in Sweden reported 510% [73], thus showing some geographical differences. Different mechanisms account for the acquired resistance to macrolides in streptococci [74].…”

Section: Gbs Clinically Relevant Antimicrobial Susceptibility Profilesupporting

confidence: 81%

Intrapartum GBS screening and antibiotic prophylaxis: a European consensus conference

Renzo

Melin²,

Berardi

et al. 2014

The Journal of Maternal-Fetal & Neonatal Medicine

153

135

View full text Add to dashboard Cite

Group B streptococcus (GBS) remains worldwide a leading cause of severe neonatal disease. Since the end of the 1990s, various strategies for prevention of the early onset neonatal disease have been implemented and have evolved. When a universal antenatal GBS screening-based strategy is used to identify women who are given an intrapartum antimicrobial prophylaxis, a substantial reduction of incidence up to 80% has been reported in the USA as in other countries including European countries. However recommendations are still a matter of debate due to challenges and controversies on how best to identify candidates for prophylaxis and to drawbacks of intrapartum administration of antibiotics. In Europe, some countries recommend either antenatal GBS screening or risk-based strategies, or any combination, and others do not have national or any other kind of guidelines for prevention of GBS perinatal disease. Furthermore, accurate population-based data of incidence of GBS neonatal disease are not available in some countries and hamper good effectiveness evaluation of prevention strategies. To facilitate a consensus towards European guidelines for the management of pregnant women in labor and during pregnancy for the prevention of GBS perinatal disease, a conference was organized in 2013 with a group of experts in neonatology, gynecologyobstetrics and clinical microbiology coming from European representative countries. The group reviewed available data, identified areas where results were suboptimal, where revised procedures and new technologies could improve current practices for prevention of perinatal GBS disease. The key decision issued after the conference is to recommend intrapartum antimicrobial prophylaxis based on a universal intrapartum GBS screening strategy using a rapid real time testing.

show abstract

Section: Gbs Clinically Relevant Antimicrobial Susceptibility Profilesupporting

confidence: 81%

Intrapartum GBS screening and antibiotic prophylaxis: a European consensus conference

Renzo

Melin²,

Berardi

et al. 2014

The Journal of Maternal-Fetal & Neonatal Medicine

153

135

View full text Add to dashboard Cite

show abstract

“…They described three alleles, one of which included the insert of 216 bp with two repeats mentioned above and found it as well strongly correlated with ST17. GBS belonging to ST17 account for a high proportion of newborn infections (3,9,14); however, whether these GBS represent a hypervirulent cluster is under discussion (13). SATR5 is the most diverse repeat locus and is responsible for a substantial part of the overall resolution obtained with this assay.…”

Section: Discussionmentioning

confidence: 99%

“…Results were available for all 126 of the strains. STs of most of the Norwegian strains were available from a previous study (3), whereas the ST of the international reference strains was available from a recent publication (22).…”

Section: Methodsmentioning

confidence: 99%

Rapid Multiple-Locus Variant-Repeat Assay (MLVA) for Genotyping of Streptococcus agalactiae

et al. 2010

View full text Add to dashboard Cite

Several methods have been used for typing of Streptococcus agalactiae (group B streptococci [GBS]). Methods currently in use may provide inadequate resolution (e.g., typing of capsular polysaccharides and surface protein) or are labor-intensive and expensive (e.g., multilocus sequence typing [MLST] or pulsed-field gel electrophoresis). This work describes the construction and use of a multiple-locus variant-repeat assay (MLVA) on 126 well-characterized human GBS strains, consisting mostly of invasive Norwegian strains and international reference strains. Based on in silico whole-genomic analysis of the genomes of strains A909, NEM316, and 2603V/R, 18 candidate loci were selected and investigated by PCR. Eleven loci showed diversity, and the five most diverse loci were used for the construction of an MLVA, consisting of a multiplex PCR followed by fragment analysis with capillary electrophoresis. The assay generated clusters which corresponded well with those observed by other methods. However, it provided a considerably higher degree of diversity, with 70 different MLVA types compared to 36 types generated by MLST. Simpson's index of diversity for the 5-locus MLVA was 0.963, compared to 0.899 for the MLST in this strain collection. MLVA results will generally be available within 2 days, which is usually faster than MLST. In our hands, MLVA of GBS represents a rapid, easy, and comparably inexpensive method for high-resolution genotyping of GBS.

show abstract

“…Strains of serotype V have been associated with the marked increase of adult invasive infections observed in North America since the 1990s (3,(10)(11)(12). Strains of this serotype, particularly those identified by multilocus sequence typing (MLST) as sequence type 1 (ST1), reportedly cause more invasive disease and have reduced susceptibility to macrolide and lincosamide antibiotics (13)(14)(15).…”

mentioning

confidence: 99%

Emergence of Serotype IV Group B Streptococcus Adult Invasive Disease in Manitoba and Saskatchewan, Canada, Is Driven by Clonal Sequence Type 459 Strains

et al. 2015

View full text Add to dashboard Cite

Serotype IV group B Streptococcus (GBS) is emerging in Canada and the United States with rates as high as 5% of the total burden of adult invasive GBS disease. To understand this emergence, we studied the population structure and assessed the antimicrobial susceptibility of serotype IV isolates causing adult invasive infection in Manitoba and Saskatchewan, Canada, between 2010 and 2014. Whole-genome sequencing was used to determine multilocus sequence typing information and identify genes encoding antimicrobial resistance in 85 invasive serotype IV GBS strains. Antimicrobial susceptibility testing was performed by standard methods. Strain divergence was assessed using genome-wide single-nucleotide polymorphism analysis. Serotype IV strains were responsible for 16.9% of adult invasive GBS infections in Manitoba and Saskatchewan during the period. The majority of serotype IV isolates (89%) were clonally related, tetracycline-, erythromycin-, and clindamycin-resistant sequence type 459 (ST459) strains that possessed genes tetM and ermTR. Genome comparisons between ST459 and serotype V ST1 GBS identified several areas of recombination in an overall similar genomic background. Serotype IV ST459 GBS strains are expanding and causing a substantial percentage of adult invasive GBS disease. This emergence may be linked to the acquisition of resistance to tetracycline, macrolides, and lincosamides.

show abstract

Molecular and phenotypic characterization of invasive group B streptococcus strains from infants in Norway 2006–2007

Cited by 18 publications

References 14 publications

Intrapartum GBS screening and antibiotic prophylaxis: a European consensus conference

Intrapartum GBS screening and antibiotic prophylaxis: a European consensus conference

Rapid Multiple-Locus Variant-Repeat Assay (MLVA) for Genotyping of Streptococcus agalactiae

Emergence of Serotype IV Group B Streptococcus Adult Invasive Disease in Manitoba and Saskatchewan, Canada, Is Driven by Clonal Sequence Type 459 Strains

Contact Info

Product

Resources

About